In a phase I trial, nadunolimab as monotherapy treatment led to reductions in the levels of the cardiovascular risk factors CRP and IL-6, further arguing in favour of a cardiovascular benefit of IL1RAP blockade.67 Similar to canakinumab, administration of nadunolimab is associated with reduced levels of neutrophils.67 Phase I studies of CAN10, which does not promote ADCC, could potentially provide insights into its effects on inflammatory biomarkers relevant to cardiovascular disease as well as rates of adverse events. Here, IL6 is linked to cardiovascular disorder.